Clinical Drug Investigation

, Volume 30, Issue 9, pp 625–641 | Cite as

Efficacy of Fixed-Dose Combination Therapy in the Treatment of Patients with Hypertension

Focus on Amlodipine/Valsartan
  • Pedro Marques da Silva
Review Article


Early initiation of rational and effective combination therapy consisting of antihypertensive drugs with two different and complementary mechanisms of actions is increasingly becoming accepted in clinical practice and by guidelines as a first-line approach to control blood pressure (BP) and prevent cardiovascular outcomes in patients with hypertension. Once-daily combination therapy provides more rapid control of BP, which is important for preventing cardiovascular events, with similar or improved tolerability compared with the component monotherapies, and improved adherence because of regimen simplification. Combination therapy with a calcium channel antagonist (calcium channel blocker [CCB]) and an inhibitor of the renin-angiotensin-aldosterone system (RAAS) is a rational approach to achieve BP goals and provide protection against renal and cardiovascular morbidity and mortality. A number of CCB/RAAS inhibitor combinations, including CCB/angiotensin-converting enzyme (ACE) inhibitor and CCB/angiotensin II type 1 receptor antagonist (angiotensin receptor blocker [ARB]) combinations are available as fixed-dose formulations. There is substantial evidence for the BP-lowering efficacy of CCB/RAAS inhibitor combinations in diverse patient populations, and their use in combination is associated with favourable tolerability and fewer adverse metabolic effects than some other combination therapies. Recent evidence from large outcome trials supports the use of CCB/RAAS inhibitor combinations for reducing the risk of cardiovascular and renal events, particularly in high-risk patients, together with evidence that the benefits of CCB/RAAS inhibitor combinations may extend beyond their efficacy in lowering BP in terms of protecting against fatal and nonfatal stroke, myocardial infarction and cardiovascular-related deaths. The efficacy of the CCB amlodipine and the ARB valsartan in lowering BP and protecting against cardiovascular events and stroke across a range of hypertensive patient populations has been established over many years. Fixed-dose amlodipine/valsartan combinations are available in many countries and have shown greater BP reductions and better BP control than the respective monotherapies in diverse patient populations, together with a favourable tolerability profile. Once-daily amlodipine/valsartan is a rational and convenient treatment option for the effective management of patients with hypertension, improving adherence to antihypertensive medication and protecting against cardiovascular and renal morbidity and mortality.


Amlodipine Valsartan Telmisartan Olmesartan Medoxomil Blood Pressure Goal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author has received honoraria from Merck Sharp & Dohme, Pfizer, Servier, Bayer and Novartis. Medical writing services for this manuscript were provided by Ray Hill, inScience Communications, a Wolters Kluwer business. Funding for this service was provided by Bial Farmacêutica, Portugal.


  1. 1.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289(19): 2560–72PubMedCrossRefGoogle Scholar
  2. 2.
    Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28(12): 1462–536PubMedGoogle Scholar
  3. 3.
    Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000; 356(9246): 1955–64PubMedCrossRefGoogle Scholar
  4. 4.
    Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165(12): 1410–9PubMedCrossRefGoogle Scholar
  5. 5.
    Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21(6): 1055–76PubMedCrossRefGoogle Scholar
  6. 6.
    ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT). JAMA 2002; 288(23): 2981–97CrossRefGoogle Scholar
  7. 7.
    Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 995–1003PubMedCrossRefGoogle Scholar
  8. 8.
    Progress Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358(9287): 1033–41CrossRefGoogle Scholar
  9. 9.
    Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362(9395): 1527–35PubMedCrossRefGoogle Scholar
  10. 10.
    Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21(11): 1983–92PubMedCrossRefGoogle Scholar
  11. 11.
    National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care. Partial update. London: Royal College of Physicians, 2006Google Scholar
  12. 12.
    Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58PubMedCrossRefGoogle Scholar
  13. 13.
    Stankus V, Hemmelgarn B, Campbell NR, et al. Reducing costs and improving hypertension management. Can J Clin Pharmacol 2009; 16(1): e151–5PubMedGoogle Scholar
  14. 14.
    Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713–9PubMedCrossRefGoogle Scholar
  15. 15.
    WaeberB, DetryJM, Dahlof B, et al. Felodipine-metoprolol combination tablet: a valuable option to initiate antihypertensive therapy? Am J Hypertens 1999; 12 (9 Pt 1): 915–20CrossRefGoogle Scholar
  16. 16.
    Waeber B, Ruilope LM. Amlodipine and valsartan as components of a rational and effective fixed-dose combination. Vasc Health Risk Manag 2009; 5(1): 165–74PubMedCrossRefGoogle Scholar
  17. 17.
    Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3): 290–300PubMedCrossRefGoogle Scholar
  18. 18.
    Frampton JE, Scott LJ. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Am J Cardiovasc Drugs 2009; 9(5): 309–30PubMedCrossRefGoogle Scholar
  19. 19.
    Jamerson KA, Nwose O, Jean-Louis L, et al. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004; 17(6): 495–501PubMedCrossRefGoogle Scholar
  20. 20.
    Messerli FH, Oparil S, Feng Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension. Am J Cardiol 2000; 86(11): 1182–7PubMedCrossRefGoogle Scholar
  21. 21.
    Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29(4): 563–80PubMedCrossRefGoogle Scholar
  22. 22.
    Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection. Drugs 2009; 69(13): 1761–76PubMedCrossRefGoogle Scholar
  23. 23.
    Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension 2005; 46(4): 637–42PubMedCrossRefGoogle Scholar
  24. 24.
    Ram CV. Antihypertensive drugs: an overview. Am J Cardiovasc Drugs 2002; 2(2): 77–89PubMedCrossRefGoogle Scholar
  25. 25.
    Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003; 326(1): 15–24PubMedCrossRefGoogle Scholar
  26. 26.
    Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369(9568): 1208–19PubMedCrossRefGoogle Scholar
  27. 27.
    Chrysant SG. Using fixed-dose combination therapies to achieve blood pressure goals. Clin Drug Investig 2008; 28(11): 713–34PubMedCrossRefGoogle Scholar
  28. 28.
    Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005; 3(1): 15–29PubMedCrossRefGoogle Scholar
  29. 29.
    Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril-Felodipine ER Factorial Study Group. Am J Cardiol 1997; 79(4): 431–5PubMedCrossRefGoogle Scholar
  30. 30.
    Poisson P, Bauer B, Schueler E, et al. Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy. Curr Med Res Opinion 1996; 13(8): 445–56CrossRefGoogle Scholar
  31. 31.
    Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. J Hum Hypertens 2001; 15(7): 495–8PubMedCrossRefGoogle Scholar
  32. 32.
    Roca-Cusachs A, Torres F, Horas M, et al. Nitrendipine and enalapril combination therapy in mild to moderate hypertension: assessment of dose-response relationship by a clinical trial of factorial design. J Cardiovasc Pharmacol 2001; 38(6): 840–9PubMedCrossRefGoogle Scholar
  33. 33.
    Scholze J, Zilles P, Compagnone D. Verapamil SR and trandolapril combination therapy in hypertension: a clinical trial of factorial design. German Hypertension Study Group. J Cardiovasc Pharmacol 1998; 45(5): 491–5Google Scholar
  34. 34.
    Ueng KC, Lin LC, Voon WC, et al. An eight-week, multi-center, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in Chinese patients with mild to moderate hypertension. Blood Press 2008; Suppl. 1: 24-31Google Scholar
  35. 35.
    Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355(9204): 637–45PubMedCrossRefGoogle Scholar
  36. 36.
    Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005; 18 (5 Pt 1): 720–30PubMedCrossRefGoogle Scholar
  37. 37.
    Black HR, Bailey J, Zappe D, et al. Valsartan: more than a decade of experience. Drugs 2009; 69(17): 2393–414PubMedCrossRefGoogle Scholar
  38. 38.
    Ibrahim MM. RAS inhibition in hypertension. J Hum Hypertens 2006; 20(2): 101–8PubMedCrossRefGoogle Scholar
  39. 39.
    Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007; 67(9): 1309–27PubMedCrossRefGoogle Scholar
  40. 40.
    Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359(9311): 1004–10PubMedCrossRefGoogle Scholar
  41. 41.
    Oparil S, Weber M. Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy. Postgrad Med 2009; 121(2): 25–39PubMedCrossRefGoogle Scholar
  42. 42.
    Stump CS, Hamilton MT, Sowers JR. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc 2006; 81(6): 796–806PubMedCrossRefGoogle Scholar
  43. 43.
    Ostergren J. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract 2007; 76Suppl. 1: S13–21PubMedCrossRefGoogle Scholar
  44. 44.
    Abuissa H, Jones PG, Marso SP, et al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46(5): 821–6PubMedCrossRefGoogle Scholar
  45. 45.
    Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev Cardiovasc Ther 2003; 1(1): 43–50PubMedCrossRefGoogle Scholar
  46. 46.
    Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21(5): 875–86PubMedCrossRefGoogle Scholar
  47. 47.
    Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370(9590): 829–40PubMedCrossRefGoogle Scholar
  48. 48.
    Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359(23): 2417–28PubMedCrossRefGoogle Scholar
  49. 49.
    Jamerson K, Bakris GL, Dahlof B, et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007; 16(2): 80–6PubMedCrossRefGoogle Scholar
  50. 50.
    Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358(15): 1547–59PubMedCrossRefGoogle Scholar
  51. 51.
    Reboldi G, Angeli F, Cavallini C, et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26(7): 1282–9PubMedCrossRefGoogle Scholar
  52. 52.
    Volpe M, Tocci G, Sciarretta S, et al. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens 2009; 27(5): 941–6PubMedCrossRefGoogle Scholar
  53. 53.
    Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906PubMedCrossRefGoogle Scholar
  54. 54.
    Gupta AK, Dahlof B, Dobson J, et al. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31(5): 982–8PubMedCrossRefGoogle Scholar
  55. 55.
    Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290(21): 2805–16PubMedCrossRefGoogle Scholar
  56. 56.
    Solomon SD, Verma A, Desai A, et al. Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension 2010; 55(2): 241–8PubMedCrossRefGoogle Scholar
  57. 57.
    Haria M, Wagstaff AJ. Amlodipine: a reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50(3): 560–86PubMedCrossRefGoogle Scholar
  58. 58.
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23): 1667–75PubMedCrossRefGoogle Scholar
  59. 59.
    Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106(19): 2454–8PubMedCrossRefGoogle Scholar
  60. 60.
    Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 2002; 40(8): 1414–21PubMedCrossRefGoogle Scholar
  61. 61.
    Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149(3): 548–57PubMedCrossRefGoogle Scholar
  62. 62.
    Wong M, Staszewsky L, Latini R, et al. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol 2002; 40(5): 970–5PubMedCrossRefGoogle Scholar
  63. 63.
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20): 1893–906PubMedCrossRefGoogle Scholar
  64. 64.
    Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022–31PubMedCrossRefGoogle Scholar
  65. 65.
    Julius S, Weber MA, Kjeldsen SE, et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48(3): 385–91PubMedCrossRefGoogle Scholar
  66. 66.
    Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004; 363(9426): 2049–51PubMedCrossRefGoogle Scholar
  67. 67.
    Kjeldsen SE, Julius S, Mancia G, et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24(7): 1405–12PubMedCrossRefGoogle Scholar
  68. 68.
    Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369(9571): 1431–9PubMedCrossRefGoogle Scholar
  69. 69.
    Sawada T, Yamada H, Dahlof B, et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART study. Eur Heart J 2009; 30(20): 2461–9PubMedCrossRefGoogle Scholar
  70. 70.
    Kohlmann Jr O, Oigman W, Mion D, et al. The “LOTHAR” study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension. Arq Bras Cardiol 2006; 86(1): 39–51PubMedCrossRefGoogle Scholar
  71. 71.
    Sharma A, Bagchi A, Kinagi SB, et al. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Clin Ther 2007; 29(12): 2667–76PubMedCrossRefGoogle Scholar
  72. 72.
    Smith TR, Philipp T, Vaisse B, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich) 2007; 9(5): 355–64CrossRefGoogle Scholar
  73. 73.
    Plosker G, Robinson D. Amlodipine/valsartan fixed-dose combination in hypertension. Drugs 2008; 68(3): 378–81CrossRefGoogle Scholar
  74. 74.
    Fogari R, Zoppi A, Derosa G, et al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. J Hum Hypertens 2007; 21(3): 220–4PubMedGoogle Scholar
  75. 75.
    Trenkwalder P, Schaetzl R, Borbas E, et al. Combination of amlodipine 10 mg and valsartan 160mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. Blood Press 2008; Suppl. 2: 13-21Google Scholar
  76. 76.
    Sinkiewicz W, Glazer RD, Kavoliuniene A, et al. Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy. Curr Med Res Opin 2009; 25(2): 315–24PubMedCrossRefGoogle Scholar
  77. 77.
    Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5mg and valsartan 160mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008; 25(5): 399–411PubMedCrossRefGoogle Scholar
  78. 78.
    Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29(2): 279–89PubMedCrossRefGoogle Scholar
  79. 79.
    Allemann Y, Fraile B, Lambert M, et al. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008; 10(3): 185–94CrossRefGoogle Scholar
  80. 80.
    Fogari R, Zoppi A, Mugellini A, et al. Efficacy and safety of two treatment combinations of hypertension in very elderly patients. Arch Gerontol Geriatr 2009; 48(3): 401–5PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Núcleo de Investigação ArterialMedicina IV-Hospital de Sta MartaLisboaPortugal

Personalised recommendations